Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Commits To Drug Comparability Protocols As ICH Q12 Takes Shape

This article was originally published in PharmAsia News

Executive Summary

In an important advance toward continual improvement of global pharmaceutical manufacturing processes, a Japanese regulatory official has promised that his agency will make it possible to use comparability protocols in Japan.

You may also be interested in...



Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

Can We Talk? US FDA Remote Records Review Missteps Worry Industry

Alkermes CRL is just the latest fallout from black-hole process.

US EUA For Lilly’s Bamlanivimab Conditioned On Additional GMP Compliance Requirements

Letter of authorization for COVID-19 therapeutic made at troubled Lilly plant requires independent third-party oversight.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel